Anti-CD324 monoclonal antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9534058-B2
Application number	US-201314377343-A
Country	US
Kind code	B2
Filing date	Feb 8, 2013
Priority date	Feb 8, 2012
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. An isolated anti-CD324 antibody or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of:
a) an antibody comprising a light chain variable region set forth as SEQ ID NO: 20, and comprising a heavy chain variable region set forth as SEQ ID NO: 21;
b) an antibody comprising a light chain variable region set forth as SEQ ID NO: 22, and comprising a heavy chain variable region set forth as SEQ ID NO: 23;
c) an antibody comprising a light chain variable region set forth as SEQ ID NO: 24, and comprising a heavy chain variable region set forth as SEQ ID NO: 25;
d) an antibody comprising a light chain variable region set forth as SEQ ID NO: 26, and comprising a heavy chain variable region set forth as SEQ ID NO: 27;
e) an antibody comprising a light chain variable region set forth as SEQ ID NO: 28, and comprising a heavy chain variable region set forth as SEQ ID NO: 29;
f) an antibody comprising a light chain variable region set forth as SEQ ID NO: 30, and comprising a heavy chain variable region set forth as SEQ ID NO: 31;
g) an antibody comprising a light chain variable region set forth as SEQ ID NO: 32, and comprising a heavy chain variable region set forth as SEQ ID NO: 33;
h) an antibody comprising a light chain variable region set forth as SEQ ID NO: 34, and comprising a heavy chain variable region set forth as SEQ ID NO: 35;
i) an antibody comprising a light chain variable region set forth as SEQ ID NO: 36, and comprising a heavy chain variable region set forth as SEQ ID NO: 37;
j) an antibody comprising a light chain variable region set forth as SEQ ID NO: 38, and comprising a heavy chain variable region set forth as SEQ ID NO: 39;
k) an antibody comprising a light chain variable region set forth as SEQ ID NO: 40, and comprising a heavy chain variable region set forth as SEQ ID NO: 41;
l) an antibody comprising a light chain variable region set forth as SEQ ID NO: 42, and comprising a heavy chain variable region set forth as SEQ ID NO: 43;
m) an antibody comprising a light chain variable region set forth as SEQ ID NO: 44, and comprising a heavy chain variable region set forth as SEQ ID NO: 45;
n) an antibody comprising a light chain variable region set forth as SEQ ID NO: 46, and comprising a heavy chain variable region set forth as SEQ ID NO: 47;
o) an antibody comprising a light chain variable region set forth as SEQ ID NO: 48, and comprising a heavy chain variable region set forth as SEQ ID NO: 49;
p) an antibody comprising a light chain variable region set forth as SEQ ID NO: 50, and comprising a heavy chain variable region set forth as SEQ ID NO: 51;
q) an antibody comprising a light chain variable region set forth as SEQ ID NO: 52, and comprising a heavy chain variable region set forth as SEQ ID NO: 53;
r) an antibody comprising a light chain variable region set forth as SEQ ID NO: 54, and comprising a heavy chain variable region set forth as SEQ ID NO: 55;
s) an antibody comprising a light chain variable region set forth as SEQ ID NO: 56, and comprising a heavy chain variable region set forth as SEQ ID NO: 57;
t) an antibody comprising a light chain variable region set forth as SEQ ID NO: 58, and comprising a heavy chain variable region set forth as SEQ ID NO: 59;
u) an antibody comprising a light chain variable region set forth as SEQ ID NO: 60, and comprising a heavy chain variable region set forth as SEQ ID NO: 61;
v) an antibody comprising a light chain variable region set forth as SEQ ID NO: 62, and comprising a heavy chain variable region set forth as SEQ ID NO: 63;
w) an antibody comprising a light chain variable region set forth as SEQ ID NO: 64, and comprising a heavy chain variable region set forth as SEQ ID NO: 65;
x) an antibody comprising a light chain variable region set forth as SEQ ID NO: 66, and comprising a heavy chain variable region set forth as SEQ ID NO: 67;
y) an antibody comprising a light chain variable region set forth as SEQ ID NO: 68, and comprising a heavy chain variable region set forth as SEQ ID NO: 69; and
z) an antibody comprising a light chain variable region set forth as SEQ ID NO: 70, and comprising a heavy chain variable region set forth as SEQ ID NO: 71.

2. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody or antigen binding fragment thereof is selected from the group consisting of:
a) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 20 for CDR-L1, residues 50-56 of SEQ ID NO: 20 for CDR-L2, and residues 89-97 of SEQ ID NO: 20 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 21 for CDR-H1, residues 50-65 of SEQ ID NO: 21 for CDR-H2 and residues 95-102 of SEQ ID NO: 21 for CDR-H3, wherein the residues are numbered according to Kabat;
b) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 22 for CDR-L1, residues 50-56 of SEQ ID NO: 22 for CDR-L2, and residues 89-97 of SEQ ID NO: 22 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2 and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat;
c) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 24 for CDR-L1, residues 50-56 of SEQ ID NO: 24 for CDR-L2, and residues 89-97 of SEQ ID NO: 24 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 25 for CDR-H1, residues 50-65 of SEQ ID NO: 25 or SEQ ID NO. 73 for CDR-H2 and residues 95-102 of SEQ ID NO: 25 for CDR-H3, wherein the residues are numbered according to Kabat;
d) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 26 for CDR-L1, residues 50-56 of SEQ ID NO: 26 for CDR-L2, and residues 89-97 of SEQ ID NO: 26 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2 and residues 95-102 of SEQ ID NO: 27 for CDR-H3, wherein the residues are numbered according to Kabat;
e) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 28 for CDR-L1, residues 50-56 of SEQ ID NO: 28 for CDR-L2, and residues 89-97 of SEQ ID NO: 28 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 29 for CDR-H1, residues 50-65 of SEQ ID NO: 29 for CDR-H2 and residues 95-102 of SEQ ID NO: 29 for CDR-H3, wherein the residues are numbered according to Kabat;
f) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 30 for CDR-L1, residues 50-56 of SEQ ID NO: 30 for CDR-L2, and residues 89-97 of SEQ ID NO: 30 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 31 for CDR-H1, residues 50-56 of SEQ ID NO: 31 for CDR-H2 and residues 95-102 of SEQ ID NO: 31 for CDR-H3, wherein the residues are numbered according to Kabat;
g) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 32 for CDR-L1, residues 50-56 of SEQ ID NO: 32 for CDR-L2, and residues 89-97 of SEQ ID NO: 32 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 33 for CDR-H1, residues 50-56of SEQ ID NO: 33 for CDR-H2

Assignees

• Stem Centrx Inc
• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Aujay Monette
• Foord Orit
• Bankovich Alex
• Hampl Johannes
• Dylla Scott J
• Liu David

Classifications

• A61K47/6897

  Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies · CPC title

• A61K47/6879

  the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• C07K16/2896 Primary

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title